Status:
COMPLETED
Study Investigating Enbrel Treatment for Ankylosing Spondylitis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
18+ years
Brief Summary
To identify the following problems and questions with respect to the safety and effectiveness of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s regu...
Eligibility Criteria
Inclusion
- Adults: Severe ankylosing spondylitis (AS) in patients who do not respond adequately to previous therapy
Exclusion
- Patients with known hypersensitivity to Enbrel or any component of the product
- Patients with sepsis or risk of sepsis
- Patients with active infections including chronic or localized infections such as tuberculosis.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
526 Patients enrolled
Trial Details
Trial ID
NCT00195416
Start Date
June 1 2005
End Date
August 1 2008
Last Update
September 16 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Gyunggi-do, South Korea, 463-707
2
Seoul, South Korea, 140-575
3
Seoul, South Korea, 143-914